Reply to "surveillance for hepatocellular carcinoma: A tale of two countries"
How to implement available data on hepatocellular carcinoma surveillance in clinical practice?
Journal of Hepatology , Volume 64 - Issue 3 p. 755- 756
To the Editor:
We appreciate the interest of Dr. Farrell and Dr. Cross in our article. In this work, we retrospectively examined 1288 patients diagnosed with hepatocellular carcinoma (HCC) in the period 2005–2012 in five academic centers in the Netherlands. Surveillance was associated with smaller tumor size, lower alpha–fetoprotein (AFP) levels, earlier tumor stage and resection/transplantation or RFA more often applied, with significantly higher survival rates.
Although Dr. Farrell and Dr. Cross are enthusiastic, we would like to draw attention to the limitations of our article. Our retrospective analysis is inherently subject to potential bias. [...]
|Journal of Hepatology|
|Organisation||Department of Gastroenterology & Hepatology|
van Meer, S, de Man, R.A, & van Erpecum, K.J. (2016). Reply to "surveillance for hepatocellular carcinoma: A tale of two countries". Journal of Hepatology, 64(3), 755–756. doi:10.1016/j.jhep.2015.12.009